VivoSeq
Infectious Disease

Ventilator-Associated Pneumonia

40

Pipeline Programs↗

14

Active Trials↗

18

Companies Involved↗

Ventilator-Associated Pneumonia is a moderately active landscape with 40 programs across 18 companies. The most active players are Basilea Pharmaceutica, Fresenius Kabi Oncology Ltd., Dexcel Pharma Technologies Ltd.. 8 therapies are approved with 15 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

25/100

Mech. Concentration

33/100

Completion Rate

71/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Basilea Pharmaceutica logo

Basilea Pharmaceutica

1 program

Phase 1F

Fresenius Kabi Oncology Ltd.

1 program

Phase 2D

Dexcel Pharma Technologies Ltd.

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

2 programs

Phase 2GSK logo

GSK

2 programs

Phase 3A

Aridis Pharmaceuticals, Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical9

Chlorhexidine Gluconate

Medline Industries

Linezolid

Pfizer

Antibiotic

Pfizer

Bacteriophage

Adaptive Phage Therapeutics, Inc.

Beta Lactam Antibiotics

Oregon Health and Science University

Phase 13

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Gentamicin

Schering-Plough

Ceftobiprole

Basilea Pharmaceutica

Phase 25

Atropine

Fresenius Kabi Oncology Ltd.

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Chlorhexidine

Dexcel Pharma Technologies Ltd.

Microbiome-Guided Inhaled Antibiotic Prophylaxis

University of Calgary

TP-122A

Unknown Sponsor

Phase 315

Interferon Gamma-1b

Horizon Therapeutics Ireland DAC

Imipenem

Pfizer

Simvastatin

Organon and Co

Ceftazidime

Philadelphia Eye Associates

Cotrimoxazole

University of California, San Francisco

Approved8

Meropenem

B. Braun Medical Inc.

Amikacin

Insmed Incorporated

Doripenem

Shionogi

Vancomycin

Hikma Pharmaceuticals LLC

Imipenem/cilastatin

Merck & Co.

Analysis

Trial Status

47

clinical trials

Completed20 · 43%
Terminated7 · 15%
Not yet recruiting6 · 13%
Unknown status5 · 11%
Recruiting4 · 9%
Active, not recruiting2 · 4%
Other3 · 6%

Clinical Trials

Trial Activity

47 trials

Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05696093·628 enrolled
Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial
Recruiting·QQilu Hospital of Shandong University·N/A·NCT06834971·508 enrolled
Antibiotic Therapy Practices for Ventilator-Associated Pneumonia (PETUNIA)
Recruiting·FFrench Society for Intensive Care·N/A·NCT06243094·1,060 enrolled
Frequent Standardized Oral Care Using Human Milk to Prevent Oral Dysbiosis and Improve Health Outcomes in Premature Infants in the Neonatal Intensive Care Unit
Recruiting·UUniversity of Florida·Preclinical·NCT06000761·218 enrolled
The Effect of Two Different Oral Care Solutions on the Prevention of Ventilator-associated Pneumonia in the Intensive Care Unit
Active, not recruiting·MMELEK UNLUGEDIK·N/A·NCT06733090·50 enrolled
Oropharyngeal Care With Colostrum, Chlorohexidine and Sodium Bicarbonate in Preventing Ventilator-associated Pneumonia in Preterm Neonates
Active, not recruiting·TTanta University·N/A·NCT07482007·80 enrolled
Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Controlled Trial
Not yet recruiting·UUniversity of Calgary·Phase 2·NCT07463339·70 enrolled
Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia
Not yet recruiting·UUniversity Hospital Fattouma Bourguiba·Phase 2/3·NCT06488794·400 enrolled
Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia
Not yet recruiting·—·N/A·NCT07202234·248 enrolled
Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia
Not yet recruiting·—·Phase 1/2·NCT06370598·15 enrolled
Developing a National Approach to Surveillance and Prevention for Neonatal Ventilator-Associated Pneumonia
Not yet recruiting·UUniversity of Alberta·N/A·NCT07109791·1,500 enrolled
A Multicentre, Double-blind, Randomized Controlled Trial of Inhaled Amikacin Versus Placebo in Critically Ill Patients With Ventilator-associated Tracheobronchitis
Not yet recruiting·UUniversity Hospital, Tours·Phase 3·NCT07665788·250 enrolled
Efficacy and Safety of Prophylactic Antibiotics in Preventing Ventilator-associated Pneumonia: A Randomized, Double Blind, Placebo-controlled Trial
Enrolling by invitation·EEsraa Salah Mohamed Abdallah Eladl·N/A·NCT07203638·100 enrolled
The Effect of Two Different Oral Care Solutions on Ventilator-Associated Pneumonia and Oral Health of Mechanically Ventilated Patients in the Intensive Care Unit
Enrolling by invitation·SSaglik Bilimleri Universitesi·N/A·NCT06966817·60 enrolled
Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria
Completed·TThammasat University·N/A·NCT02574130·60 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)